BFRI
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Biofrontera Inc. (BFRI) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B); its weakest is Momentum (C-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | B (3.4) | B (3.4) | C+ (2.6) | C- (2.0) | C+ (2.6) | C+ (2.8) |
| 2026-11-10 | B (3.4) | B (3.5) | C+ (2.6) | C (2.2) | C+ (2.6) | B- (2.9) |
| 2026-11-03 | B (3.4) | B (3.5) | C+ (2.6) | C (2.2) | C+ (2.7) | B- (2.9) |
| 2026-10-27 | B (3.4) | B (3.5) | C+ (2.7) | C (2.4) | C+ (2.6) | B- (2.9) |
| 2026-10-20 | B (3.4) | B (3.5) | C+ (2.7) | C+ (2.8) | C+ (2.6) | B- (3.0) |